NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$736.08

-5.40 (-0.73%)

(As of 11/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $727.00
▼
$740.00
50-Day Range: $684.63
▼
$759.91
52-Week Range: $538.01
▼
$769.63

Volume: 515,102 shs
Average Volume: 704,968 shs
Market Capitalization: $80.16 billion

P/E Ratio: 15.52
Dividend Yield: N/A
Price Target: $766.81

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.59 Rating Score
Upside/Downside: 4.2% Upside
$766.81 Price Target
Short Interest: Healthy
1.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 0.10
Based on 9 Articles This Week
Insider Trading: Selling Shares
$23.24 M Sold Last Quarter
Proj. Earnings Growth: -2.07%
From $38.08 to $37.29 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

498th out of 1,038 stocks

Pharmaceutical Preparations Industry

224th out of 510 stocks

2.3

Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.59, and is based on 15 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $766.81, Regeneron Pharmaceuticals has a forecasted upside of 4.2% from its current price of $736.08.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
1.72% of the float of Regeneron Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regeneron Pharmaceuticals has recently decreased by 0.56%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Regeneron Pharmaceuticals has received a 63.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Cardiovascular system medication (C)" products. See details.
Environmental Sustainability
The Environmental Impact score for Regeneron Pharmaceuticals is -1.65.

1.2

News and Social Media Coverage

News Sentiment
Regeneron Pharmaceuticals has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
Only 17 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,241,958.00 in company stock.
Percentage Held by Insiders
Only 8.99% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
84.92% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to decrease by -2.07% in the coming year, from $38.08 to $37.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 15.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 15.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.44.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

November 10, 2022 | marketbeat.com

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (REGN)

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

November 26, 2022 | finance.yahoo.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness.

November 30, 2022 | Legacy Research (Ad)

Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”

Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. Revealed here: the name and ticker of the #1 stock.

November 26, 2022 | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Plew Daniel P. Van Sells 11,972 Shares

November 25, 2022 | finance.yahoo.com

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

November 24, 2022 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN) and Medios AG (OtherMEDOF)

November 22, 2022 | markets.businessinsider.com

Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer

November 22, 2022 | finance.yahoo.com

There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price

November 30, 2022 | Legacy Research (Ad)

Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”

Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. Revealed here: the name and ticker of the #1 stock.

November 22, 2022 | finance.yahoo.com

Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

November 18, 2022 | finance.yahoo.com

Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 28% CAGR over the last three years

November 17, 2022 | msn.com

Regeneron Pharmaceuticals's Return On Capital Employed Overview

November 17, 2022 | finance.yahoo.com

CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron

November 12, 2022 | finance.yahoo.com

2 Top Biotech Stocks to Buy in November

November 11, 2022 | nasdaq.com

Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU

November 11, 2022 | marketwatch.com

Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY

November 10, 2022 | msn.com

$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today

November 8, 2022 | finance.yahoo.com

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

November 8, 2022 | finance.yahoo.com

Regeneron Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

November 6, 2022 | finance.yahoo.com

Subdued Growth No Barrier To Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price

November 4, 2022 | finance.yahoo.com

Regeneron accelerates research spending as drug pipeline grows

November 4, 2022 | finance.yahoo.com

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

November 3, 2022 | markets.businessinsider.com

Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates

November 3, 2022 | seekingalpha.com

Regeneron Q3 sales sans COVID products grow on back of blockbuster Eylea

November 3, 2022 | msn.com

Regeneron Pharmaceuticals: Q3 Earnings Insights

November 3, 2022 | finance.yahoo.com

Regeneron Reports Third Quarter 2022 Financial and Operating Results

November 3, 2022 | finance.yahoo.com

Regeneron Pharmaceuticals Q3 tops earnings and revenue marks

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings: 11/04/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/03/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:REGN
CUSIP: 75886F10
CIK: 872589
Web: www.regeneron.com
Phone: (914) 847-7000
Fax: 914-347-2113
Employees: 10,368
Year Founded: 1988

Price Target and Rating

Average Stock Price Forecast: $766.81
High Stock Price Forecast: $970.00
Low Stock Price Forecast: $575.00
Forecasted Upside/Downside: +4.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.59
Research Coverage: 22 Analysts

Profitability

EPS (Most Recent Fiscal Year): $47.43
Trailing P/E Ratio: 15.52
Forward P/E Ratio: 19.33
P/E Growth: 2.15
Net Income: $8.08 billion
Net Margins: 39.17%
Pretax Margin: 44.04%
Return on Equity: 31.16%
Return on Assets: 23.61%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 5.36
Quick Ratio: 4.52

Sales & Book Value

Annual Sales: $16.07 billion
Price / Sales: 4.99
Cash Flow: $80.80 per share
Price / Cash Flow: 9.11
Book Value: $172.92 per share
Price / Book: 4.26

Miscellaneous

Outstanding Shares: 108,902,000
Free Float: 99,112,000
Market Cap: $80.16 billion
Optionable: Optionable
Beta: 0.20

Social Links

Key Executives

Dr. Leonard S. Schleifer M.D. (Age 69)
Ph.D., Founder, Pres, CEO & Director
Comp: $6.47M

Dr. George D. Yancopoulos M.D. (Age 62)
Ph.D., Scientific Founder, Pres, Chief Scientific Officer & Director
Comp: $6.4M

Mr. Robert E. Landry Jr. (Age 58)
Exec. VP of Fin. & CFO
Comp: $1.9M

Mr. Joseph J. LaRosa (Age 63)
Exec. VP, Gen. Counsel & Sec.
Comp: $1.75M

Dr. Andrew J. Murphy Ph.D. (Age 63)
Exec. VP of Research
Comp: $1.57M

Mr. Daniel P. Van Plew (Age 49)
Exec. VP and GM of Industrial Operations & Product Supply
Comp: $1.77M

Ms. Patrice Gilooly
Sr. VP of Quality Assurance & Operations

Mr. Christopher R. Fenimore (Age 51)
Sr. VP, Head of Accounting & Controller

Mr. Gerald Underwood
Sr. VP of Technical Operations

Mr. Bob McCowan
Sr. VP of IT & Chief Information Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.
What is Regeneron Pharmaceuticals' stock price forecast for 2023?: 22 equities research analysts have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $575.00 to $970.00. On average, they expect the company's stock price to reach $766.81 in the next year. This suggests a possible upside of 4.2% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.
How have REGN shares performed in 2022?: Regeneron Pharmaceuticals' stock was trading at $631.52 at the beginning of the year. Since then, REGN stock has increased by 16.6% and is now trading at $736.08.
View the best growth stocks for 2022 here.
When is Regeneron Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast.
How were Regeneron Pharmaceuticals' earnings last quarter?: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.81 by $5.56. The biopharmaceutical company earned $3.45 billion during the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.17% and a trailing twelve-month return on equity of 31.16%. The business's quarterly revenue was up 50.5% compared to the same quarter last year. During the same quarter last year, the firm earned $7.68 EPS.
Read the conference call transcript.
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?: 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).
What is Regeneron Pharmaceuticals' stock symbol?: Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Who are Regeneron Pharmaceuticals' major shareholders?: Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.71%), Vanguard Group Inc. (7.94%), State Street Corp (4.64%), Price T Rowe Associates Inc. MD (1.61%), Putnam Investments LLC (1.01%) and Bank of New York Mellon Corp (0.94%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.
How do I buy shares of Regeneron Pharmaceuticals?: Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Regeneron Pharmaceuticals' stock price today?: One share of REGN stock can currently be purchased for approximately $736.08.
How much money does Regeneron Pharmaceuticals make?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.16 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.
How many employees does Regeneron Pharmaceuticals have?: The company employs 10,368 workers across the globe.
Does Regeneron Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial